Search
Close this search box.

FDA approved five NMEs in April

DATA GRAPHICS | Data Byte

Day One, X4 and ImmunityBio each received their first drug approvals 

By Gunjan Ohri, Data Content Analyst

May 2, 2024 10:42 PM UTC

Three of the five new medicines FDA approved in April marked the transition of their manufacturers to commercial-stage companies. 

Day One Biopharmaceuticals Inc. (NASDAQ:DAWN) and  X4 Pharmaceuticals Inc. (NASDAQ:XFOR) each gained their first-ever approval for a pediatric indication…